Actively Recruiting
Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives
Led by Beijing Tiantan Hospital · Updated on 2024-12-19
400
Participants Needed
1
Research Sites
4 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the long-term outcomes of conservative management in patients with moyamoya disease and their first-degree relatives. Moyamoya disease is a chronic condition involving narrowing of arteries in the brain, caused by genetic, inflammatory, immunological, and environmental factors. The exact cause is still unclear, and understanding long-term effects of non-surgical treatments could provide insights into the disease's development. Participants will receive conservative medical treatment tailored to their symptoms, including antiplatelets, antiepileptics, antihypertensives, and vasodilators. The study includes both patients diagnosed with moyamoya disease and their first-degree relatives who may carry genetic variants. The research team will observe these groups over several years without surgical intervention to evaluate treatment outcomes. During the study, participants will be monitored with regular assessments at baseline and multiple follow-up points up to five years. These include cerebrovascular event tracking, neurological outcome evaluations, brain imaging using methods like CTP, CTA, MRA, and HR-MRI, and blood tests for biomarkers. The study aims to better understand disease progression and treatment effects over time, with ongoing follow-up to ensure comprehensive data collection.
CONDITIONS
Brief Title
Long-term Outcomes of Conservative Management in Patients with Moyamoya Disease and Their First-degree Relatives (LAMORA)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age between 2 and 60 years
- Clinical diagnosis of moyamoya disease, including unilateral and bilateral forms
- Receiving medical treatment with antiplatelets, antiepileptics, antihypertensives, or vasodilators based on symptoms
- Able to understand the study purpose and risks and provide informed consent, or have a legal representative consent
- Able to comply with study follow-up visits
You will not qualify if you...
- Having other diseases like systemic vasculitis, neurofibroma, meningitis, sickle cell disease, Down's syndrome, or prior basilar radiotherapy
- History of cardiogenic embolism such as atrial fibrillation, valvular disease, or cardiac valve replacement
- Allergy to contrast agents
- Treated with surgical revascularization (direct, indirect, or combined)
- Unable or unwilling to cooperate with examinations or having serious other illnesses
- Unlikely to return for follow-up visits
- Any other condition deemed unsuitable by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants who are receiving conservative management for Moyamoya disease or are first-degree relatives with genetic variants are observed over time to monitor cerebrovascular events and neurological outcomes.
Visits at baseline, 6 months, 1 year, 2 years, and 5 years
Trial Site Locations
Total: 1 location
1
Beijing Tiantan Hospital Capital Medical University
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Q
Qian Zhang, MD
C
Chaofan Zeng, MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here